Clinical trials
Malignant Neoplasm clinical trials
Below are recruiting malignant neoplasm clinical trials, each written for real people, not researchers. We’re tracking 482 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05461664Recruiting
Avapritinib for advanced GIST without PDGFRA exon 18 changes
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
GuangzhouAges 18 years+ - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT06859203Recruiting
PET scan study for men with rising PSA after prostate cancer treatment
This study tests a newer type of PET scan (fluciclovine) in men whose previous PSMA PET scan was negative or unclear. It aims to find if the fluciclovine PET can better detect where the cancer has returned, helping guide treatment decisions.
Augsburg, BavariaAges 18 years+ - NCT07302347RecruitingPhase 1/Phase 2
Study of pembrolizumab for different cancers in Japan
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
Nagoya, Aichi-kenAges 6 months+ - NCT07286149RecruitingPhase 1/Phase 2
Study of MK-1084 plus other treatments for lung cancer
This trial tests a new drug (MK-1084) combined with other treatments for people with a specific type of advanced lung cancer (non-small cell, non-squamous) that has a KRAS G12C mutation. It is for those whose cancer has worsened after prior immunotherapy and chemotherapy.
Clermont, FloridaAges 18 years+ - NCT07276373RecruitingPhase 1/Phase 2
Nenocorilant with nivolumab for advanced solid tumors
This trial tests a new drug called nenocorilant combined with nivolumab (an immunotherapy) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07271355RecruitingPhase 3
Pressurized chemo spray for appendix or colorectal cancer spread in abdomen
This trial tests a new way to deliver chemotherapy directly into the abdomen as a pressurized spray, using a drug called mitomycin. It is for people with appendix or colorectal cancer that has spread to the lining of the abdomen and cannot be removed by surgery.
Goodyear, ArizonaAges 18 years+ - NCT06119789RecruitingPhase 2
Personalized treatment for rare cancers using tumor markers
This trial tests whether using a precise medicine based on your tumor's unique biomarker can help treat rare cancers more effectively. It aims to offer personalized therapy when standard options are limited.
OsloAges 16–99 - NCT07252739RecruitingPhase 2
Study of pembrolizumab plus MK-1084 for KRAS G12C lung cancer
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. The goal is to see if the combination works better than current treatments.
Clermont, FloridaAges 18 years+ - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
New Brunswick, New JerseyAges 18 years+ - NCT07244835RecruitingPhase 1
A study of DEG6498 for advanced solid tumors
This trial tests a new drug, DEG6498, for people with advanced solid tumors that have not responded to other treatments. It may be an option if your cancer has a BRAF mutation or is a type of liver cancer called HCC.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06505577Recruiting
Comparing Tumor Size Before and After Breast Cancer Surgery
This study compares the size of a breast tumor measured before surgery (using imaging tests like mammogram or ultrasound) with the actual size found after the tumor is removed. It helps understand how accurate preoperative measurements are for patients having breast cancer surgery.
IncheonAges 19 years+ - NCT06630793Recruiting
Comparing types of radiation for anal cancer
This study compares standard radiation (IMRT) with a newer, more precise type (IMPT) both given alongside chemotherapy for anal cancer. It aims to see which is better at controlling cancer and reducing side effects.
Mumbai, MaharashtraAges 18–80 - NCT07209111RecruitingPhase 2
Testing Calderasib for advanced solid tumors with KRAS G12C mutation
This trial tests a new drug, Calderasib (MK-1084), for people with advanced solid tumors that have a specific KRAS G12C mutation and aren't getting better with standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Baltimore, MarylandAges 18 years+ - NCT07162675Recruiting
Step count and treatment response in breast cancer patients
This study looks at how your daily step count, measured by a smartwatch, relates to how well your breast cancer responds to treatment before surgery. It may help show if being more active during chemotherapy leads to better outcomes.
Ankara, YenimahalleAges 18 years+ - NCT07131007Recruiting
Early warning system for immunotherapy side effects
This study is for people with cancer who are already receiving immunotherapy (checkpoint inhibitors). It aims to build an early warning system to help detect and manage possible organ damage or other side effects from the treatment, using advanced testing to keep you safer.
Shijiazhuang, HebeiAges 18–80 - NCT06383520RecruitingEarly Phase 1
PET imaging for GPC3 in liver cancer
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
Wuhan, HubeiAges 18–65 - NCT07067138Recruiting
Genetic testing to guide treatment for advanced breast cancer
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
Bethesda, MarylandAges 18–120 - NCT07072143Recruiting
Study on children with rare tumors
This study is looking at children and teens with very rare tumors to learn more about these conditions and improve future care. It aims to gather information from patients treated at participating centers.
Padova, ItalyAges birth–18 years - NCT07042581RecruitingPhase 4
Revaree Plus for vaginal dryness in breast cancer survivors
This trial tests a vaginal insert called Revaree Plus to see if it helps breast cancer survivors who have vaginal dryness or pain from hormone therapy. It may be a good option if you are on an aromatase inhibitor or tamoxifen and have discomfort.
Basking Ridge, New JerseyAges 18 years+ - NCT07026422RecruitingPhase 2
Combination immunotherapy with chemoradiation for high-risk rectal cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and radiation before surgery for people with a specific type of high-risk rectal cancer. The goal is to see if adding these drugs can improve treatment results.
Jinan, ShandongAges 18–75 - NCT06208371RecruitingPhase 3
Local treatment vs. chemo for colorectal cancer with many liver spots
This trial tests whether treating all liver tumors with surgery, ablation, or radiation is better than continuing standard chemotherapy for people with colorectal cancer that has spread only to the liver. It's for those whose liver tumors have been controlled by initial chemotherapy and are considered removable.
Guangzhou, GuangdongAges 18 years+ - NCT06979596RecruitingPhase 2
A study of MK-5684 for certain solid tumors
This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.
Anchorage, AlaskaAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Los Angeles, CaliforniaAges 1 month–17 years
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignant neoplasm?
- Yes. Clin2 currently lists 482 recruiting malignant neoplasm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignant neoplasm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignant neoplasm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.